Literature DB >> 23282972

Plasmablastic transformation of low-grade B-cell lymphomas: report on 6 cases.

Daniel Martinez1, Alexandra Valera, Nhora Silva Perez, Luz Fernanda Sua Villegas, Blanca Gonzalez-Farre, Carla Sole, Eva Gine, Armando Lopez-Guillermo, Gaël Roue, Salome Martinez, Francesc Sant, Krzysztof Warzocha, Tadeusz Robak, Magdalena Czader, Neus Villamor, Lluis Colomo, Elias Campo, Antonio Martinez.   

Abstract

Histologic transformation of low-grade B-cell lymphoma to diffuse large B-cell lymphoma is associated with poor prognosis. Although plasma cell differentiation is common in these lymphomas, an overt plasmablastic transformation (PBL-T) has been only rarely reported. We report 6 cases of PBL-T occurring in 3 chronic lymphocytic leukemias (CLL) and 3 follicular lymphomas. Five patients were men, and the mean age was 65 years (range, 52 to 72 y). None of them had history of immunodeficiency. In 3 cases the PBL-T occurred 34 to 85 months after the initial diagnosis, and in 3 it was detected simultaneously with the small cell component at diagnosis. All patients received chemotherapy after transformation, and 4 died 4 to 24 months after this diagnosis. In 3 cases, PBL-T occurred in an extranodal site. All PBL-Ts had immunoblastic morphology with admixed plasma cells, were CD20 and PAX5 negative, expressed λ light chain, and 5 were CD138 positive. All cases were negative for HHV8, and only 1 PBL-T was Epstein-Barr virus positive. Evidence of a clonal relationship between the small cell and PBL-T components was found in 5 cases. In 2 CLL cases, both components had 13q deletions, and in all follicular lymphoma cases both components harbored the t(14;18) translocation. MYC translocations were observed in 2 cases transformed from a CLL. In conclusion, PBL-T expands the clinicopathologic spectrum of the transformation of low-grade B-cell lymphomas. These transformed tumors are clinically, histologically, and phenotypically similar to primary plasmablastic lymphomas, but they are not associated with immunodeficiency and rarely have Epstein-Barr virus infection or MYC alterations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23282972     DOI: 10.1097/PAS.0b013e31826cb1d1

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  11 in total

Review 1.  The heterogeneity of follicular lymphomas: from early development to transformation.

Authors:  Luc Xerri; Stephan Dirnhofer; Leticia Quintanilla-Martinez; Birgitta Sander; John K C Chan; Elias Campo; Steven H Swerdlow; German Ott
Journal:  Virchows Arch       Date:  2015-10-19       Impact factor: 4.064

Review 2.  Plasmablastic lymphoma following combination treatment with fludarabine and rituximab for nongastric mucosa-associated lymphoid tissue lymphoma: a case report and review of literature.

Authors:  Jia-Zhu Wu; Ke Min; Lei Fan; Li Wang; Ji Xu; Jian-Yong Li; Wei Xu
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

3.  Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.

Authors:  Bo-Jung Chen; Chang-Tsu Yuan; Ching-Fen Yang; Chung-Han Ho; Yen-Kuang Lin; Ying-Zhen Su; Hsiu-Chu Chou; Shih-Sung Chuang
Journal:  Virchows Arch       Date:  2022-06-03       Impact factor: 4.535

4.  Chronic Lymphocytic Leukemia with Divergent Richter's Transformation into a Clonally Related Classical Hodgkin's and Plasmablastic Lymphoma: A Case Report.

Authors:  Gorana Gasljevic; Mateja Grat; Veronika Kloboves Prevodnik; Biljana Grcar Kuzmanov; Barbara Gazic; Luca Lovrecic; Helena Podgornik
Journal:  Case Rep Oncol       Date:  2020-02-13

Review 5.  MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management.

Authors:  Qingqing Cai; L Jeffrey Medeiros; Xiaolu Xu; Ken H Young
Journal:  Oncotarget       Date:  2015-11-17

6.  Concurrent chronic lymphocytic leukemia/small lymphocytic lymphoma and hairy cell leukemia: clinical, pathologic and molecular features.

Authors:  Ifeyinwa Emmanuela Obiorah; Ivo M B Francischetti; Hao-Wei Wang; Inhye E Ahn; Weixin Wang; Mark Raffeld; Robert J Kreitman; Adrian Wiestner; Katherine R Calvo
Journal:  Leuk Lymphoma       Date:  2020-08-05

7.  Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment.

Authors:  Kristo Marvyin; Eirik Brekka Tjønnfjord; Unni Mathilde Breland; Geir Erland Tjønnfjord
Journal:  BMJ Case Rep       Date:  2020-09-29

8.  Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma.

Authors:  Ying Liu; Fatima Jelloul; Yanming Zhang; Tapan Bhavsar; Caleb Ho; Mamta Rao; Natasha E Lewis; Robert Cimera; Jeeyeon Baik; Allison Sigler; Filiz Sen; Mariko Yabe; Mikhail Roshal; Ola Landgren; Ahmet Dogan; Wenbin Xiao
Journal:  Am J Surg Pathol       Date:  2020-06       Impact factor: 6.298

9.  Plasmablastic Lymphoma with Coexistence of Chronic Lymphocytic Leukemia in an Immunocompetent Patient: A Case Report and Mini-Review.

Authors:  Eleftheria Hatzimichael; Konstantina Papathanasiou; Ioannis Zerdes; Stefanos Flindris; Alexandra Papoudou-Bai; Eleni Kapsali
Journal:  Case Rep Hematol       Date:  2017-11-20

Review 10.  The broad landscape of follicular lymphoma: Part II.

Authors:  Stefano Fratoni; Magda Zanelli; Maurizio Zizzo; Francesca Sanguedolce; Valentina Aimola; Giulia Cerrone; Linda Ricci; Alessandra Filosa; Giovanni Martino; Antonella Maria Fara; Valerio Annessi; Alessandra Soriano; Stefano Ascani
Journal:  Pathologica       Date:  2020-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.